Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Katelyn Mason

Physician Assistant Myrtle Beach, SC Physician Assistant

NPI 1356984322 CMS profile 7219526

210 Village Center Blvd Ste 140, Myrtle Beach, SC 29579

Open in the dashboard

General payments

$10,450

299 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Katelyn Mason of Myrtle Beach, SC is reported in the CMS Open Payments database as having received $10,450 across 299 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,938 42
2024 General $1,102 62
2023 General $272 13
2022 General $1,050 59
2021 General $2,088 123

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Katelyn Mason
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Katelyn Mason were reported at $5,938. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Katelyn Mason Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,088 $132 $37–$438 $132
2022 $1,050 $155 $48–$522 $149
2023 $272 $167 $52–$557 $160
2024 $1,102 $178 $55–$600 $164
2025 $5,938 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $6,077 79 payments
  2. Teva Pharmaceuticals USA, Inc. $1,358 80 payments
  3. ACADIA Pharmaceuticals Inc $374 12 payments
  4. Pfizer Inc. $282 17 payments
  5. US WorldMeds, LLC $190 2 payments
  6. Lundbeck LLC $185 10 payments
  7. UCB, Inc. $156 6 payments
  8. Biohaven Pharmaceuticals, Inc. $154 12 payments
  9. Novartis Pharmaceuticals Corporation $152 8 payments
  10. Alexion Pharmaceuticals, Inc. $138 5 payments
  11. Other $1,384 68 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,547 293 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,809 5 payments
  3. Travel and Lodging $94 1 payment
Products named General payments · program years 2021–2025
  1. UBRELVY $3,260 47 payments
  2. QULIPTA $2,980 40 payments
  3. AJOVY $889 58 payments
  4. NUPLAZID $343 10 payments
  5. AUSTEDO $309 10 payments
  6. NURTEC ODT Pain $220 14 payments
  7. NURTEC ODT Primary Care $188 14 payments
  8. Gocovri $177 1 payment
  9. Austedo XR $161 12 payments
  10. BOTOX $139 8 payments
  11. Other $2,271 114 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 47 drugs

Part D claims

2,981

Median for Physician Assistant: 241

Drug cost

$594,467

Median for Physician Assistant: $4,110

Branded share of claims

26.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Xr Deutetrabenazine Brand 18 $125,002
Aimovig Autoinjector Erenumab-Aooe Brand 72 $99,445
Nurtec Odt Rimegepant Sulfate Brand 54 $77,345
Ubrelvy Ubrogepant Brand 47 $72,650
Qulipta Atogepant Brand 46 $67,832
Nuplazid Pimavanserin Tartrate Brand 12 $61,135
Ajovy Autoinjector Fremanezumab-Vfrm Brand 23 $23,146
Memantine Hcl Generic 321 $14,582
Rivastigmine Rivastigmine Tartrate Brand 71 $5,521
Gabapentin Generic 296 $5,299

The 10 drugs with the highest cost, of 47 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$143,694

Of which drugs: $38,649

Medicare patients

679

Average age 75

Services billed

9,421

354 women, 325 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Depression 34%
Diabetes 31%
Ischemic heart disease 30%
Alzheimer's or dementia 28%
Chronic kidney disease 25%
Atrial fibrillation 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 21 8,000 $38,647

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Gocovri
  • US WorldMeds, LLC $177
$177 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $114
$114 18 —
UBRELVY
  • AbbVie, Inc. $88
$88 47 —
BOTOX
  • AbbVie, Inc. $87
$87 — 8,000
ULTOMIRIS
  • Alexion Pharmaceuticals, Inc. $71
$71 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

299 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record